Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma http://clinicaltrials.gov/show/NCT01870726
Drug: INC280
INC280 will be given at the starting dose of 200mg twice daily.
Drug: Buparlisib
Buparlisib will be given at the starting dose of 50mg once daily.
Exclusion Criteria
Fasting plasma glucose > 120mg/dL or > 6.7 mmol/L